Good afternoon, everyone. Welcome to Cross Country Healthcare's Earnings Conference Call for the Second Quarter 2022. Please be advised that this call is being recorded and a replay of this webcast will be available on the company's website. Details for accessing the audio replay can be found in the company's earnings release issued this afternoon. At the conclusion of the prepared remarks, I will open the lines for questions. I would now like to turn the call over to Josh Vogel, Cross Country Healthcare's Vice President of Investor Relations. Thank you. And please go ahead, sir.

Thank you, and good afternoon, everyone. I'm joined today by our President and Chief Executive Officer, John Martins, as well as Bill Burns, our Chief Financial Officer; Dan White, Chief Commercial Officer; and Marc Krug, Group President of Delivery. Today's call will include a discussion of our financial results for the second quarter of 2022, as well as our outlook for the third quarter. A copy of our earnings press release is available on our website at crosscountryhealthcare.com. Please note that certain statements made on this call may constitute forward-looking statements. These statements reflect the company's beliefs based upon information currently available to it. As noted in our press release, forward-looking statements can vary materially from actual results and are subject to known and unknown risks, uncertainties and other factors, including those contained in the company's 2021 annual report on Form 10-K and quarterly reports on Form 10-Q, as well as in other filings with the SEC. The company does not intend to update guidance or any of its forward-looking statements prior to the next earnings release. Additionally, we reference non-GAAP financial measures such as adjusted EBITDA or adjusted earnings per share. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for or superior to those calculated in accordance with US GAAP. More information related to these non-GAAP financial measures is contained in our press release. Also during this call, we may refer to pro forma when normalized numbers pertain to our most recent acquisitions as though the results were included or excluded from the prior periods presented. With that, I will now turn the call over to our Chief Executive Officer, John Martins.

Thanks, Josh, and thank you to everyone for joining us this afternoon. The end of the second quarter was my first full quarter as CEO and I continue to be amazed by the capability of this organization to execute across so many fronts, with an unwavering commitment to deliver best-in-class service to the thousands of clients we support and the tens of thousands of clinicians and professionals we place. The culture at Cross Country has never been stronger, as evidenced by the recent certification we received for Great Place to Work. For those that may not know, this award is based entirely on what our current employees have to say, standing workplace culture, employee experience and leadership. I believe that our commitment to core values and thirst for innovation has become a beacon to thousands of employees who have joined Cross Country in delivering on its mission. We're a company committed to clinical excellence, ethical practices and help equity which has positioned us as the partner of choice for thousands of client. Beyond the continued strong performance for both revenue and adjusted EBITDA, we have once again exceeded the high-end of our guidance ranges. The second quarter also marks a new chapter for Cross Country as we continue to evolve our tech-enabled workforce solutions with the launch of our newest product Intellify. Intellify is our very first proprietary cloud-based multi-tenant vendor management system that will not only be used across our managed service programs, will also serve as the backbone for a vendor neutral solution that will further diversify our business. I'll get into more detail on our technology investments in a few minutes. So let me first share some comments on our results. Consolidated revenue of $754 million exceeded our expectations and was up more than double over the…

Thanks, John, and good afternoon, everyone. Our stronger than expected second quarter performance for revenue and adjusted EBITDA was once again driven by strong execution across multiple fronts with at least double-digit year-over-year growth in every line of business. While higher bill rate played a role, the primary driver for the growth came from an increase in billable hours across all lines of business within Nurse and Allied as well as higher days build for our physician staffing segment. Consolidated revenue for the quarter was $754 million, up 120% over the prior year and down sequentially approximately 4% on the normalization of bill rates for our travel business. Our solid top-line performance fueled another quarter of strong earnings with adjusted EBITDA of nearly $84 million with a double-digit adjusted EBITDA margin of 11%. Gross margin was 22.6%, which was up 70 basis points over the prior year, primarily on improved bill pay spread related to our travel business. Sequentially, gross margin improved approximately 40 basis points, primarily related to the annual payroll tax reset in the first quarter. Margin should gradually improve over time as the bill pay spreads continue to normalize. Though, as John mentioned that near-term pressures could distort the trajectory. Gross profit was $170 million, representing an increase of 135% over the prior year, driven primarily by the record number of professionals on assignment. Turning to the segments, Nurse and Allied reported revenue of $731 million, representing an increase of 131% over the prior year and a 4% decline sequentially. Our largest business, travel nurse and allied experienced yet another record quarter with the highest number of travelers on assignment in the company's history. Sequentially, billable travel hours rose by 3%, while average bill rates fell by 7%. John already touched on this, but let me just…

Thank you. Our first question is from Kevin Fischbeck with Bank of America. You may go ahead.

Great, thanks. So I guess everyone's trying to figure out how to think about the bill rates. A bit hard to talk about 2023 at this point. But I guess just in general, if we think about that Q4 kind of run rate number that you plan to exit the year. Would you expect to grow off of that run rate number? And is there that -- should we still be thinking about that 9%, 10% margin in 2023 and beyond?

Yeah, I'll start and I'll have Bill way in. But yes, we anticipate we'd still be able to grow at those bill rates. And I think what we're looking at, first of all, I'd like to just start off by saying, we're really pleased with where we are right now in our results that we've had and we feel really good about the future. And when we look about launching our Intellify business and what that's going to mean to help us to be able to win more MSP deals, we think that's going to be really a key into helping us drive more growth into the fourth quarter and beyond. And so when we look even when we're talking about our MSPs, we've added a lot of firepower over the last 12 months in our sales organization. We've really reorganized that organization. And as we mentioned in our prepared marks, we landed three deals, MSPs deals recently worth over $85 million and we have a pretty robust pipeline of more deals coming in. A matter of fact we have two verbal award commitments that we're contracting through right now, which will put another $70 million additional to the $85 million in the win column shortly. So we feel that there is a lot of room for growth in the future. I'll have Bill speak to the --

Yeah. Kevin, I think your question is really on the bill rates and the trajectory after -- as we get into 2023. I would say at this point we're not modeling a significant rise, of course, in 2023 I think -- we think it levels off as we go into the start of the year. Longer term of course rates will start to see inching forward their normal kind of mid-single digit percentage increase, low mid-single digit that we normally have experienced. But I think '23 will be a level year for the most part for us as we go into it. We don't really have a better lens at this point.

Okay, that's helpful. And I guess it was interesting to get the color about the orders throughout the quarter and then again start Q3 up again. I guess I just don't know on top of my head what that should normally look like seasonally. Can you just like maybe give us some fair reference of what a 50% at the end of the quarter and July. What would that normally look like in a normal year?

Yeah, Kevin, again this is Bill. We would not have seen this kind of level of movement in a normal year pre-pandemic. We did not have this kind of order volatility. Yeah, there were normal fluctuations in demand, but it was in low single, high single, double-digit kind of movements. So it wasn't this kind of a 50% swing within one quarter. And I think what we really experienced was, as we're coming out of the first quarter as the pandemic kind of step down from that last surge. Demand pull back as was expected, hit that trough point as we got into the early days of Q2 and then sort of unexpectedly the demand has been inching forward every single week and is carried on into the third quarter to the point now where, to John's point in the prepared remarks, we're up even into the third quarter, up another 11%. There is really no corollary on a historic pre-pandemic basis that I could point you to. It's been more wild swings ever since the pandemic has been out there.

Yeah, I'd add Kevin that as we're moving and transitioning from the pandemic to the endemic, we don't really have a good feel of what that looks like in terms of seasonality needs, right? We'd be anticipating right now to see flu season order starting to come in and that preparing for flu season. But we're also looking at seeing a higher number of COVID cases that popped up over the last six weeks. And so while hospitalizations are down, we're still seeing that portion of some need still being COVID-related. So it's a little hard to say, how to place that. But look at the end of the day the number of orders we have now for the rest of our lines of business are up double than where they were pre-pandemic. And we anticipate that to continuing to see that the needs in the future.

And I just one other comments, I think what we saw early in Q2 was probably a bit artificial as systems were trying to get contingent labor under control, delaying giving out orders and the like. So what we're seeing is really the pendulum swinging back to the more normal level for the market given the shortages.

Yeah. And I'd say what specialties you're seeing up are, we're seeing respiratory, we're seeing ICU, but we're also seeing pediatrics and we're also seeing OR, which kind of shows you we’re getting back into more normal cycle, but I think there is, again, still not having that -- not having the crystal ball in front of us. It's going to be really hard to predict really how the demand ebbs and flows in the next coming six months.

All right. Great. Thank you.

Thank you. The next question is from Brian Tanquilut with Jefferies. You may go ahead.

Good afternoon, everyone. I'm actually on for Brian. This is Taji, and thank you for taking my question. So, first -- my first question is, can you provide some insight on the recruiting environment for nurses in terms of -- are you seeing a lot of new applications come to the table, what does that look like and also initiatives that you've taken to boost recruitment and retention? And then this is a follow-up to when thinking about your fill rates, so looking at the percentage of orders that you've received versus those that you can complete. Can you provide some color on how that's progressed throughout the quarter and how you're thinking about that moving forward for the rest of the year? Thanks.

Sure. Thanks for the question, Taji. And in terms of applicants, we have seen a record number of applicants over the last six months and we continue to heavily invest in our programmatic advertising, as well as our digital marketing strategy. We have -- we're seeing a lot more of -- 65% of all of our travelers are now millennials or younger defined as people age 41 or younger. And so we're seeing a heavy swing to a lot of our applicants coming into the workforce and wanting to become and join this gig economy we've been speaking about for a while. And so we're very pleased still seeing a large number of supply being attracted to travel nursing as we move forward. And in terms of our fill rates, we look at the rate, we look at fill rates really from our MSPs and the orders that we can actually control and we have the exclusivity on. And in those we look at our capture rate. So our fill rates on our MSPs are in the high 90% and really what we focus on next is our capture rate. And our capture rate remains, as we said in prepared remarks, just a little -- about 70%, well south of 70%.

And does that conclude your question?

Yes, thank you.

Thank you. The next question is from Tobey Sommer with Truist Securities. You may go ahead.

Thank you. Based on your commentary, when would you forecast Nurse and Allied revenue to sort of plateau and then inflect higher?

Yeah. So, Tobey, this is Bill. I guess I'd say based on where -- how we're looking at bill rates, we would think that with the most significant declines coming in the Q3 and Q4 for the year that our fourth quarter would expected to be the trough on that point of it and volumes are expected to continue to inch forward. They won't outstrip the bill rate reductions into the fourth quarter. But as we get into early 2023, the expectation is volume begins to overtake those rate changes.

And I wanted to ask a question about your MSP capture. You said low-60s, could -- high-60s, sorry, could you give us a little bit of context for how that has ebbed and flowed from, I don't know, pre-pandemic through the pandemic and maybe give us some context about whether you would have room to increase that, should demand sort of moderate at some point? Thank you.

Sure. Thanks Toby for the question. This is John. And pre-pandemic we were in the high-50s and we inch that up to the high-70s. We have the capability and ability to bring that up even higher from the 70s. But as we stated before, we really keep it around the 70s and we really don't want to be too much higher than that because what we do is, we take our excess supply and bring it to potential new clients to actually feed our pipeline of MSPs. But if we needed to, it's always a lever we could pull, but right now with our pipeline of MSPs that we have there is really no reason we believe that we'll continue to really accelerate our wins in MSPs. The other exciting thing is, as we mentioned with the launch of Intellify, we're also going to be able now to enter into the VMS vendor neutral space, which we have never participated before. And with that -- that is a multi-billion dollar space where we offer clients currently or prior to Intellify just an MSP accountable model which many clients do want that service. But there is a segment of clients out there, again, in a multi-billion dollar of segment that want a vendor choice program or a vendor neutral program. And for us allowing to now have that offering, we feel that it will help continue to diversify our business. And those of course are on a higher margin business. So we're very excited about that new offering and really being able to take some market share in that vendor neutral space.

That makes sense. Thank you. With respect to that Intellify in terms of just transferring your own book from third-party vendor to your own platform, what is the -- could you quantify the cost savings associated with that and the time period over which the transitioning might take place?

Yeah, Tobey, it's Bill. I guess I'll just give you the context on the cost. I mean for us you can imagine that the spend under management for today attracts a fee for us, right, because almost all the technology that's used there is third-party so that cost is anywhere from 75 bps to a 1%, so round numbers, you're talking north of $10 million in annualized savings on a normalized basis, and I think the deployment or the rollout schedule, I don't know Dan if you want to speak to that a little bit.

Yeah. Hi, Tobey. How are you? We currently have 10 clients and implementation are expected to go live throughout Q3 and a similar number already scheduled for Q4, which include some of these new signings. And so we feel really good about the ability to not only convert some but add some new ones and build the capacity to actually grow faster than that as we get into next year. We're building some new muscles in that regard. And so I feel really good about where we are right now. I mean, some of that has to do with the fact that we've been able to continue to add really strong experienced talent to our already energized team. And for me, that goes all the way from sort of sales through client management, implementation, ongoing optimization of our accounts. So I'm just feeling really good about our ability to continue to deliver value to our customers.

And Tobey, if I were going to just throw, there is a couple of factors that dictate the speed at which we can convert active MSPs, one has to do with the level of wins and the number of new accounts that we have coming on. Obviously, those accounts will want to make sure that they get deployed on the technology more rapidly than we convert some of the old ones, so there's not as much disruption. But we are moving with pace to move our programs over to this technology, but some of it will also be on the clients their mix and their needs.

Yeah, this is John, Tobey. I think realistically over 12 to 18 month period you'll see us go and win other technologies, but again we're in -- we want to be thoughtful about how we go and do this. We want to make sure we take care of the clients first and foremost and the patients to make sure they have the staff there. So -- and as we develop and build our software, it's very iterative process. And so some complex -- some hospitals are more complex that will go on a little slow rent, some complex -- some hospitals little bit easier that will go a little faster. So it will be over time period that we continue to do. And as we keep, as Bill noted, I think it's important, as we keep winning new MSPs and accelerate that as well as moving into the vendor neutral space and winning clients there. Those clients will also move on quicker which will slow us down a little a bit to bring on those other -- the older clients.

Thanks. Last question from me and I'll get back in the queue. The multiple of the stock is coming under pressure even as results have surged and we're hearing that private company M&A transaction might still be pretty respectable and in some cases higher. Are you receiving any sort of outreach and any inquiries into interested parties in acquiring the company and the business?

No, no, we think we're well undervalued as most people out there. And I think if you look where the analyst and you guys have us at our target prices we're well below where those are. But we're continuing to focus on showing people what we're doing, we're making the right moves and really continuing to look forward to keeping growing the business. And if we look at where we were pre-COVID as an organization, we were $30 million EBITDA company. Our trailing 12 months is nearly $300 million. And as we've stated, as we look to exit the year at north of $500 million revenue run rate in the high single low double-digit EBITDA, if you look at 2023, that puts us north of $2 billion and pick your number between $160 million to $240 million of EBITDA. We think the story is out there and our stock will get lifted fairly quickly as people see that. We've moved from the pandemic to the endemic and that -- this company has been turned around from every aspect of that business. When Kevin Clark came back 3.5 years ago we started taking and looking at Cross Country, which had a good foundation, but we needed to shore up those foundations. And we found -- we shored up those foundations starting with people, process and technology and culture and we hit every one of those marks. And if you look at what we've done over the last three years, we came through and we've proven that we've delivered that we've turned starting from the inside out of this company, we've turned it around and shored up the foundation. Now as we launch accelerated dynamic MSP sales team and more team that are winning deals and will continue to win deals top -- couple that with our external facing technology of Intellify for our clients and our internal portal, which we launched this year for a greater, more efficient candidate experience, but we see there is -- there is no reasons to be talking to anybody other than us to where the shareholders will have greater value as we keep continuously deliver shareholder value.

And does that conclude your questions?

It does, yes.

Thank you. Our next question is from Bill Sutherland with The Benchmark Company. You may go ahead.

Hello, everybody. John or Bill, discuss your capital priorities going forward, particularly given the fact that the cash is going to turn positive and probably very strongly for the foreseeable future?

Hey, Billy. We both can answer here. I think, first of all, it's a topic of conversation at Cross Country more so than it ever has been, predominantly because we have more options. I think you look back to Cross Country pre the turnaround and we were generating $20 million $30 million of cash a year. It's a whole of the ballgame when you're looking at north of $100 million in positive cash flows on a continuing basis. So options are more available to us now. I think we always been opportunistic at looking at what returns the most value. But I think a more dedicated strategy around that is what we're working on right this minute. I'd say that the predominant use of cash will continue to be funding growth. So that's both organic, the investments in products like Intellify. I wouldn't be surprised if in the future we continue to ramp our spend on technology that we've already announced for this year. And then of course the opportunity for M&A to tuck into build scale in some of our other businesses that have higher margins is certainly a play for us. Servicing debt, we did just pay down $50 million optional on our term loan because the interest cost on that is pretty significant. I would not say that the next best thing is to continue to pay down debt. There's some amount of debt that's healthy for a company like Cross Country to have on its books. And so share repurchases are certainly something that's in our line of sight that we're evaluating internally. And I think that that will be something that we'll look to do in the second half. If I fast forward the clock and we were sitting on all the cash collections that we know are coming in, I think you would see more concerted effort on the share repurchase side.

Great. I just wanted a little clarification, John. You were -- when you were discussing the puts and takes on bill rates and pay rates looking out six months and how that could move the gross margin a little up or down. I just want to understand a little more clearly what you're thinking in terms of those lead in lags, I guess, to better put them, puts and takes?

Sure. So as we start looking to go from the crisis rate assignments that we had where we were working on a little bit lower margin on some of those rates, on some of those assignments to the more normal travel assignments. We anticipate that we'll be able to pick up some margin. Now what we've said in our prepared remarks is, during the third quarter we've had some mid assignment rate changes where an assignment had changed over from a crisis assignment to the hospital the crisis clinician and really needs to had a normal travel rate assignment. And in that case, when those clinicians turn over and agree to take the travel rate assignment, we try to keep those clinicians as whole as we can and take even a lower margin. So we would anticipate to have a little bit of lower margin hit -- have margin hit in the third quarter because we want to retain the clinicians and keep the hospitals whole, making sure that we have care at the bedside from the hospitals. And then as we go into the fourth quarter and these -- those mid assignment reads, once we have a new assignment, we're able to then increase the gross margin. The other opportunity we have in our margin is as we look at the whole portfolio of our businesses. So as we start going and rolling out our vendor neutral platform, that's a much higher margin business that will also increase margins overall for the business. And then as we look at our home health business, that's a higher margin business and that's growing at a double digit growth rate. Our education business which was interesting in Q2, we were up over 20% in revenue for education business and that's up against 2018 and 2019 pre COVID numbers. So not only are we back to the revenue of pre COVID in education, but we're actually growing fairly rapidly. The education segment in this country has experienced the same severe shortages and crisis that we saw in healthcare. As during the pandemic many of the healthcare professionals and education professionals and teachers had the same fatigue and burnout because they had distance learning and had to go into schools with not enough PPE as we had in healthcare. So we're seeing a great prices -- education professional shortage that is not anticipated to be alleviated for the next several years. So we have invested heavily in that business to also help grow that business, but that will also help us -- of our -- to increase our margins, which will help our overall portfolio margins. But to answer your question, yes, we do expect in fourth quarter to see a normalized -- increased margins for the normalized travel assignments.

And then remind me, what's the size of the education platform now? I would think that would be one where bolt-ons would be very attractive given the dynamics you just discussed?

You're spot on, Bill. the education business for us aside from the summer months where you move that revenue stream, but it's on track for like a $60 million run rate business for us on an annual basis and that's excluding the summer months. So it's definitely a place that we are looking at intensely for opportunities to find the right play to have the tuck ins. It is a heavily diversified market. So it's -- some of the companies are a bit smaller out there that we're looking at. But there's opportunities there.

Okay. Thanks everybody.

Thank you.

Thank you. Our next question is from Tobey Sommer with Truist Securities. You may go ahead.

Thanks. I was wondering if you could describe the complexion of new nurse -- travel nurse applicants. That's kind of aren't in your database and you think are new to the market. We do get quits from the BLS, but that's kind of emphasizing directional and your data would be perhaps a little bit more timely.

Yes, Tobey, I mean, are you asking -- when you say the demographics like the age brackets, I mean, two thirds are millennials or younger. We've seen an eight fold increase in Gen Z applicants. But we've had increases across all age -- the entire age spectrum, but I'm not sure if that answers the question you were looking for.

And I missed part of the -- few minutes ago, but I heard you talk about the balance sheet and cash flow. Do you intend to stick with the current kind of capital structure or are there ways that that can be optimized given the improved margins and cash flow outlook?

Yes, absolutely, Tobey. I think we are evaluating the debt structure right now. Today, we're in an ABL and we have a subordinated term loan. We're of a size and scale now that it opens up more options for us whether that is looking at the pro rata market or looking at term loan Bs. So there's opportunities to put in a more permanent flexible, scalable piece of debt on the business. So that's something that's on the line of sight. I do think the ABL for us has fit historically given the peaks and valleys that we've seen in our business and it scales with size of the receivables, but at some point an ABL gets outstripped by your ability to borrow off your -- multiple of your EBITDA or your profitability. So it's definitely on the table right now. The markets -- I'm sure you're aware that markets have not been the most open from the debt -- capital markets debt perspective. It seems to be that things are easing a bit. So as we inch into the back half, I think that will be something we'll be evaluating more closely.

Okay. Thank you very much for entertaining the additional questions.

You're welcome.

Thanks, Tobey.

Thank you. As there are no further questions, ladies and gentlemen, this does conclude the Q&A period. I'll now turn it back over to John Martin for closing remarks.

Before signing off, I'd like to take a moment to recognize the life and achievements of one of our Board members, Daryl Friedman, who sadly passed in late June. Daryl had been a Director and an audit committee member since 2018 as well as a compensation committee member since mid-2020. He was a unique and inspiring soul, a highly recognized entrepreneur and executive as well as an accomplished triathlete. He will be greatly missed and our thoughts and prayers are with his family during this difficult time. In closing, I'd like to thank everyone for participating in today's call. We look forward to updating you on our progress on the next call.

Ladies and gentlemen, this does conclude today's conference call. Thank you for your participation. You may now disconnect.